Table 1 Details of clinical characteristics of SCLC patients.

From: Mapping the immune landscape in small cell lung cancer by analysing expression of immuno-modulators in tissue biopsies and paired blood samples

Parameter

Number of patients (n)

 

Total number of patients

40

 

Age range (median—51.5 years)

 < 25 years

0

0%

 25–50 years

12

30%

 51–75 years

27

67.5%

 > 75 years

1

2.5%

Male:female ratio

36 males:4 females

9:1

Smoking index (SI) (available in 25 of 40 cases)

 < 250

2

8%

 250–500

10

40%

 501–700

13

52%

 > 700

0

0%

History of tobacco chewing

3

7.5%

Associated co-morbidities

1 patient had diabetes mellitus

2.5%

ES-SCLC disease

29

72.5%

LS-SCLC disease

11

27.5%

ECOG scores at evaluation

 Score 1

8

20%

 Score 2

29

72.5%

 Score 3

3

7.5%

Follow up

 DOD

3

7.5%

 Progressive disease

34

85%

 Lost to follow up

3

7.5%

  1. DOD died of disease, ECOG Eastern Co-operative Oncology Group-performance status scale, ES-SCLC extensive stage small cell lung cancer, LS-SCLC limited stage small cell lung cancer.